touchRESPIRATORY were delighted to speak with Dr. Patrick Lyons (Washington University School of Medicine, St. Louis, MO, USA) to discuss the outcomes from using corticosteroids as a treatment for the distinct subphenotypes of SARS-CoV-2 pneumonia.
The abstract ‘Novel EHR-Derived SARS-CoV-2 Pneumonia Subphenotypes Show Divergent Clinical Outcomes with Differential Responses to Corticosteroids.’ (Abstract number: P858) was presented at ATS 2022, 13-18 May 2022.
Questions
- Could you tell us a little about the two subphenotypes that have been identified in COVID-19-related acute respiratory distress syndrome?
- What were the aims and design of the study you are presenting?
- What were the findings of the study?
- What are the implications of these findings in terms of corticosteroid use in hospitalised patients with COVID-19?
- What questions remain unanswered and what future studies are planned?
Disclosures: Patrick Lyons has nothing to disclose in relation to this video interview.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ATS meeting 2022.
